Luyan Pharmaceutical (002788.SZ) announced first-half results. Net profit to mother was 143 million yuan, down 7.46% year on year

According to the Zhitong Finance App, Luyan Pharmaceutical (002788.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 10.583 billion yuan, an increase of 1.75% over the previous year. Net profit attributable to shareholders of listed companies was 143 million yuan, a year-on-year decrease of 7.46%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 138 million yuan, a year-on-year decrease of 9.88%. Basic earnings per share were $0.37.

During the reporting period, the country continued to deepen the regulatory reform of the whole chain of pharmaceuticals and medical consumables, and promoted the transformation of the industry from “scale expansion” to “value innovation” through normalization and refinement of collection; the digital intelligence upgrade of health insurance fund supervision was carried out in parallel, and the Health Insurance Class C Catalogue (Commercial Insurance Innovative Drug Catalogue) was officially linked to the basic medical insurance catalogue, forming normalized adjustments, and accelerated the construction of a “health insurance+commercial insurance” diversified payment pattern; in the face of industry changes and local policy orientation, the company standardized operations, forge ahead, and continued to advance the “four comprehensive” “four” Implementation of strategic initiatives such as “four new” and “four integrations” to maintain business performance Smooth.